Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: RSV Immunization Clear all
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Missoula, Montana • Norfolk, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Safety of RSV Preventive Monoclonal Antibody

NCT07158814
View directory record Official record
Conditions
Fever, Adverse Event Following Immunisation
Interventions
Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Weeks to 30 Weeks
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults

NCT07171164
View directory record Official record
Conditions
Older Adults Without Any Specific Clinical Condition, Social Networks, RSV Immunization, Vaccine Uptake
Interventions
Motivate Aim: CHW text message reminders and counseling, Motivate Aim: CHW text message reminders only, Activate Aim: CHW text message reminders and counseling, Activate Aim: CHW text message reminders only
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

NCT06551506
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Abrysvo, Beyfortus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

NCT07050732
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total), Placebo
Biological · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups

NCT06639386
View directory record Official record
Conditions
Vaccine Hesitancy, Vaccine Refusal
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 vaccine, Control
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
3,855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Not yet recruiting Phase 4 Interventional

RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients

NCT07296120
View directory record Official record
Conditions
CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic
Interventions
Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
Biological
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed No phase listed Observational

An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants

NCT02273882
View directory record Official record
Conditions
Respiratory Syncytial Virus Hospitalizations
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Up to 12 Months
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
44
States / cities
Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 22, 2026, 10:41 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

NCT03191383
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Jul 22, 2026, 10:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06252285
View directory record Official record
Conditions
RSV Immunisation
Interventions
RSVt Vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
6,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 4 Interventional

Prevention of RSV Infections in Bone Marrow Transplant Recipients

NCT00001903
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
RSV Polyclonal Immunoglobulin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 10:41 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

NCT06564194
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV), Infectious Disease
Interventions
JCXH-108, Placebo
Biological · Other
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Jupiter, Florida • New Orleans, Louisiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

NCT02247726
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection)
Drug
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
7
States / cities
Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

NCT02624947
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV F vaccine with adjuvant, Formulation buffer
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
4,636 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
49
States / cities
Birmingham, Alabama • Cullman, Alabama • Fort Defiance, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

Promotion of RSV Immunization Through Multiple Efforts

NCT06640868
View directory record Official record
Conditions
Pregnancy, Vaccination
Interventions
MyChart nurse message, SMFM video, Visual aid
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

NCT06866405
View directory record Official record
Conditions
RSV Infection
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Active, not recruiting No phase listed Observational

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

NCT07249320
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
ABRYSVO
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 50 Years
Enrollment
1 participant
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
10,212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
55
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting No phase listed Observational

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

NCT06172660
View directory record Official record
Conditions
RSV Infection
Interventions
Nirsevimab
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 12 Months
Enrollment
3,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06397768
View directory record Official record
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

NCT05639894
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candiate formulation 1, RSV vaccine candidate formulation 2, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
25
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 22, 2026, 10:41 AM EDT